CYP2C19 and transient ischemic attack: Does CYP2C19 loss-of-function metabolizer status, which blunts metabolism of clopidogrel to its active form, modify the degree of benefit of ticagrelor-aspirin or clopidogrel-aspirin for patients with minor stroke or transient ischemic attack?